Hanmi Pharmaceutical Shares Jump on Eli Lilly Partnership for Sonefpeglutide Development

Hanmi Pharmaceutical’s stock rose sharply on June 1, 2026, after the company announced a partnership with Eli Lilly to develop sonefpeglutide, an investigational drug. The collaboration sent Hanmi shares higher, though financial terms were not disclosed. The deal combines Hanmi’s drug delivery platform with Lilly’s clinical and commercial resources to advance the therapy, which targets metabolic conditions. Sonefpeglutide has shown promise in early-stage studies, and the partnership aims to accelerate its development program. Hanmi will receive an upfront payment and is eligible for milestone payments, the company said without providing specifics. The agreement underscores continued dealmaking in the biopharma sector as large drugmakers seek to bolster pipelines through external innovation.